Orforglipron

Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist. FDA approved Foundayo on April 1, 2026 for use with a reduced-calorie diet and increased physical activity to reduce excess weight and maintain weight reduction in adults with obesity, or overweight plus at least one weight-related condition. This is a current product approval, not a forecast for 2027–2028.

The July 2026 label covers weight management, including eligible adults who have type 2 diabetes; it does not establish a separate diabetes-treatment indication or approval for every product sold as orforglipron.

The product label describes GLP-1 receptor activity that reduces calorie intake through effects on appetite. Orforglipron also stimulates insulin secretion and reduces glucagon in a glucose-dependent manner, and delays gastric emptying. Its oral small-molecule identity does not establish greater safety or better adherence than injectable treatments.

In ATTAIN-1, 3,127 adults without diabetes were randomized for 72 weeks. The journal treatment-regimen analysis reported mean weight changes of −7.5%, −8.4% and −11.2% with investigational 6, 12 and 36 mg doses, versus −2.1% with placebo. Adverse events led to discontinuation in 5.3–10.3% versus 2.7%.

The current label, Table 6 presents investigational-formulation results as equivalent marketed Foundayo doses: 5.5, 9 and 17.2 mg. Its Trial 1 estimates are −7.4%, −8.3% and −11.1%, versus −2.1%, using its specified analysis. These are distinct source presentations; trial milligrams must not be copied onto marketed tablets.

In ATTAIN-2, 1,613 adults with overweight or obesity and type 2 diabetes were randomized. The treatment-regimen estimates at 72 weeks were −5.1%, −7.0% and −9.6% across investigational doses, versus −2.5%. Separate trials of other drugs cannot establish a head-to-head ranking.

Randomized trials support weight reduction in the studied populations, with improvements in selected cardiometabolic measures. Oral administration provides an option for people who prefer tablets; it does not guarantee easier adherence, superior tolerability or a particular individual result.

In ATTAIN-MAINTAIN, participants previously treated with tirzepatide (205) or semaglutide (171) were randomized to oral orforglipron or placebo. Among participants who had reached a weight plateau, model estimates indicated maintenance of 74.7% versus 49.2% of prior weight reduction after tirzepatide, and 79.3% versus 37.6% after semaglutide, at 52 weeks. These percentages describe retention of earlier weight loss, not loss of that percentage of body weight. There was no continued-injectable comparator, so the trial does not show that switching is equivalent to staying on an injection.

The July 2026 Foundayo label starts at 0.8 mg once daily, then 2.5 mg after at least 30 days and 5.5 mg after at least another 30 days. Further levels are 9, 14.5 and 17.2 mg, with at least 30 days at the current level and escalation based on response and tolerability. The maximum is 17.2 mg daily; interactions can require a lower maximum or avoidance.

Tablets are taken whole, with or without food, no more than one per day. These are instructions for the named marketed product. Investigational 6/12/36 mg study doses are not its tablet strengths. The label includes missed-dose and restart instructions; a prescriber should select and supervise treatment rather than converting an online research dose.

The current prescribing information includes a boxed thyroid C-cell tumor warning and contraindicates use with a personal or family history of medullary thyroid carcinoma, MEN2, or serious hypersensitivity. Orforglipron was not pharmacologically active in rats or mice and did not produce tumors in those species; the boxed warning addresses GLP-1 receptor-dependent rodent findings with other active agents and uncertain human relevance. Routine calcitonin or thyroid-ultrasound monitoring is of uncertain value for early detection, rather than a universal screening recommendation.

Common effects include nausea, constipation, diarrhea, vomiting and other gastrointestinal symptoms. Warnings also address pancreatitis, severe gastrointestinal reactions, volume-depletion kidney injury, hypoglycemia with insulin or secretagogues, hypersensitivity, retinopathy monitoring in patients with a history, gallbladder disease and aspiration around anesthesia. Severe gastroparesis and severe hepatic impairment have specific label limits. Another GLP-1 agonist is not recommended concurrently.

The label describes CYP3A4/OATP1B interactions and a simvastatin dose limit. Pregnancy recognition calls for discontinuation; oral contraceptive users are advised to switch to a non-oral method or add a barrier method for 30 days after initiation and each escalation. Oral delivery does not remove these risks, and cross-trial rates do not prove a tolerability advantage.

Editorial source check dated October 26, 2026. Linked primary abstracts and relevant official product or regulatory sections were read; journal full texts and every library page in this compound family were not reviewed. This is not clinician sign-off or an individualized treatment assessment.